[go: up one dir, main page]

AU9449398A - Use of csaidtm compounds for the management of uterine contractions - Google Patents

Use of csaidtm compounds for the management of uterine contractions

Info

Publication number
AU9449398A
AU9449398A AU94493/98A AU9449398A AU9449398A AU 9449398 A AU9449398 A AU 9449398A AU 94493/98 A AU94493/98 A AU 94493/98A AU 9449398 A AU9449398 A AU 9449398A AU 9449398 A AU9449398 A AU 9449398A
Authority
AU
Australia
Prior art keywords
csaidtm
management
compounds
uterine contractions
contractions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU94493/98A
Inventor
Samir Ahmed Alvi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ip2ipo Innovations Ltd
Original Assignee
Imperial College Innovations Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Imperial College Innovations Ltd filed Critical Imperial College Innovations Ltd
Publication of AU9449398A publication Critical patent/AU9449398A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU94493/98A 1997-10-10 1998-10-08 Use of csaidtm compounds for the management of uterine contractions Abandoned AU9449398A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US6161497P 1997-10-10 1997-10-10
US60061614 1997-10-10
PCT/GB1998/003015 WO1999018942A1 (en) 1997-10-10 1998-10-08 Use of csaidtm compounds for the management of uterine contractions

Publications (1)

Publication Number Publication Date
AU9449398A true AU9449398A (en) 1999-05-03

Family

ID=22036940

Family Applications (1)

Application Number Title Priority Date Filing Date
AU94493/98A Abandoned AU9449398A (en) 1997-10-10 1998-10-08 Use of csaidtm compounds for the management of uterine contractions

Country Status (5)

Country Link
EP (1) EP1021173A1 (en)
JP (1) JP2001519381A (en)
AU (1) AU9449398A (en)
CA (1) CA2316296A1 (en)
WO (1) WO1999018942A1 (en)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5916891A (en) 1992-01-13 1999-06-29 Smithkline Beecham Corporation Pyrimidinyl imidazoles
CA2294057A1 (en) 1997-06-13 1998-12-17 Smithkline Beecham Corporation Novel pyrazole and pyrazoline substituted compounds
WO1998057966A1 (en) 1997-06-19 1998-12-23 Smithkline Beecham Corporation Novel aryloxy substituted pyrimidine imidazole compounds
US7301021B2 (en) 1997-07-02 2007-11-27 Smithkline Beecham Corporation Substituted imidazole compounds
US6562832B1 (en) 1997-07-02 2003-05-13 Smithkline Beecham Corporation Substituted imidazole compounds
US6489325B1 (en) 1998-07-01 2002-12-03 Smithkline Beecham Corporation Substituted imidazole compounds
EP1041989A4 (en) 1997-10-08 2002-11-20 Smithkline Beecham Corp Novel cycloalkenyl substituted compounds
US6858617B2 (en) 1998-05-26 2005-02-22 Smithkline Beecham Corporation Substituted imidazole compounds
ATE266399T1 (en) 1998-08-20 2004-05-15 Smithkline Beecham Corp NEW SUBSTITUTED TRIAZOLE COMPOUNDS
US6184226B1 (en) * 1998-08-28 2001-02-06 Scios Inc. Quinazoline derivatives as inhibitors of P-38 α
ATE336484T1 (en) 1998-08-29 2006-09-15 Astrazeneca Ab PYRIMIDINE COMPOUNDS
ES2274634T3 (en) 1998-08-29 2007-05-16 Astrazeneca Ab PIRIMIDINE COMPOUNDS.
JP2002528506A (en) 1998-11-04 2002-09-03 スミスクライン・ビーチャム・コーポレイション Pyridin-4-yl or pyrimidin-4-yl substituted pyrazine
GB9828511D0 (en) 1998-12-24 1999-02-17 Zeneca Ltd Chemical compounds
GB9905075D0 (en) 1999-03-06 1999-04-28 Zeneca Ltd Chemical compounds
GB9907658D0 (en) 1999-04-06 1999-05-26 Zeneca Ltd Chemical compounds
US7122666B2 (en) 1999-07-21 2006-10-17 Sankyo Company, Limited Heteroaryl-substituted pyrrole derivatives, their preparation and their therapeutic uses
GB9919778D0 (en) 1999-08-21 1999-10-27 Zeneca Ltd Chemical compounds
DE19948417A1 (en) * 1999-10-07 2001-04-19 Morphochem Ag Imidazole derivatives and their use as medicines
AU1783201A (en) 1999-11-23 2001-06-04 Smithkline Beecham Corporation 3,4-dihydro-(1h)quinazolin-2-one compounds as csbp/p38 kinase inhibitors
AU1782301A (en) 1999-11-23 2001-06-04 Smithkline Beecham Corporation 3,4-dihydro-(1h)quinazolin-2-one compounds as csbp/p39 kinase inhibitors
ATE281439T1 (en) 1999-11-23 2004-11-15 Smithkline Beecham Corp 3,4-DIHYDRO-(1H)CHINAZOLINE-2-ONE COMPOUNDS AS CSBP/P38 KINASE INHIBITORS
GB0004887D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0004890D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0004888D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0004886D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
US7235551B2 (en) 2000-03-02 2007-06-26 Smithkline Beecham Corporation 1,5-disubstituted-3,4-dihydro-1h-pyrimido[4,5-d]pyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases
GB0007371D0 (en) 2000-03-28 2000-05-17 Astrazeneca Uk Ltd Chemical compounds
GB0016877D0 (en) 2000-07-11 2000-08-30 Astrazeneca Ab Chemical compounds
GB0021726D0 (en) 2000-09-05 2000-10-18 Astrazeneca Ab Chemical compounds
CA2437248A1 (en) * 2001-02-02 2002-08-15 Takeda Chemical Industries, Ltd. Jnk inhibitor
GB0103926D0 (en) 2001-02-17 2001-04-04 Astrazeneca Ab Chemical compounds
GB0113041D0 (en) 2001-05-30 2001-07-18 Astrazeneca Ab Chemical compounds
GB0205688D0 (en) 2002-03-09 2002-04-24 Astrazeneca Ab Chemical compounds
WO2003076434A1 (en) 2002-03-09 2003-09-18 Astrazeneca Ab 4- imidazolyl substuited pyrimidine derivatives with cdk inhibitiory activity
GB0205693D0 (en) 2002-03-09 2002-04-24 Astrazeneca Ab Chemical compounds
GB0205690D0 (en) 2002-03-09 2002-04-24 Astrazeneca Ab Chemical compounds
AR039241A1 (en) 2002-04-04 2005-02-16 Biogen Inc HETEROARILOS TRISUSTITUIDOS AND METHODS FOR ITS PRODUCTION AND USE OF THE SAME
EP1560488B1 (en) 2002-11-05 2010-09-01 Glaxo Group Limited Antibacterial agents
GB0311274D0 (en) 2003-05-16 2003-06-18 Astrazeneca Ab Chemical compounds
GB0311276D0 (en) 2003-05-16 2003-06-18 Astrazeneca Ab Chemical compounds
GB0327975D0 (en) * 2003-12-02 2004-01-07 Imp College Innovations Ltd Methods of treatment
WO2005053706A1 (en) * 2003-12-02 2005-06-16 Imperial College Innovations Limited Use of a cyclopentenone prostaglandin for delaying for the onset and/or preventing the continuation of labour
TW200528101A (en) 2004-02-03 2005-09-01 Astrazeneca Ab Chemical compounds
MXPA06012512A (en) * 2004-04-28 2007-02-08 Tanabe Seiyaku Co 4- 2- (cycloalkylamino) pyrimidin-4-yl ! - (phenyl) - imidazolin-2- one derivatives as p38 map- kinase inhibitors for the treatment of inflammatory diseases.
MY143245A (en) 2004-04-28 2011-04-15 Mitsubishi Tanabe Pharma Corp 4- 2-(cycloalkylamino)pyrimidin-4-yl-(phenyl)-imidazolin-2-one derivatives as p38 map-kinase inhibitors for the treatment of inflammatory diseases
CA2584368A1 (en) * 2004-10-19 2006-04-27 Arqule, Inc. Synthesis of imidazooxazole and imidazothiazole inhibitors of p38 map kinase
CA2623374A1 (en) 2005-09-30 2007-04-05 Astrazeneca Ab Imidazo [1,2-a] pyridine having anti-cell-proliferation activity
EP2914265A4 (en) * 2012-11-05 2016-04-13 Nant Holdings Ip Llc Substituted indol-5-ol derivatives and their therapeutical applications
WO2020093098A1 (en) * 2018-11-07 2020-05-14 The University Of Melbourne Novel compounds for the treatment of respiratory diseases

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2191013T3 (en) * 1992-03-04 2003-09-01 Cell Therapeutics Inc XANTINA COMPOUNDS HYDROXYLATED ENANTIOMERS.
US5593992A (en) * 1993-07-16 1997-01-14 Smithkline Beecham Corporation Compounds
IL110296A (en) * 1993-07-16 1999-12-31 Smithkline Beecham Corp Imidazole compounds process for their preparation and pharmaceutical compositions containing them
EP0715619A4 (en) * 1993-08-23 1997-03-19 Immunex Corp TUMOR NECROSIS ALPHA FACTOR SECRETION INHIBITORS
US5543150A (en) * 1993-09-15 1996-08-06 Columbia Laboratories, Inc. Method of progesterone delivery and affect thereof
WO1995022546A1 (en) * 1994-02-18 1995-08-24 Cell Therapeutics, Inc. Intracellular signalling mediators
EP1013764A1 (en) * 1994-07-05 2000-06-28 Steeno Research Group A/S Immunomodulators
CA2210322A1 (en) * 1995-01-12 1996-07-18 Smithkline Beecham Corporation Novel compounds
IL118544A (en) * 1995-06-07 2001-08-08 Smithkline Beecham Corp Imidazole derivatives, process for their preparation and pharmaceutical compositions comprising them
ATE360419T1 (en) * 1995-09-19 2007-05-15 Solomon B Margolin USE OF N-SUBSTITUTED PYRIDONES AS TUMOR NECROSIS FACTOR ALPHA INHIBITORS
KR19990077164A (en) * 1996-01-11 1999-10-25 스티븐 베네티아너 A novel substituted imidazole compound
WO1997026278A1 (en) * 1996-01-18 1997-07-24 Steeno Research Group A/S Synthetic il-10 analogues

Also Published As

Publication number Publication date
JP2001519381A (en) 2001-10-23
CA2316296A1 (en) 1999-04-22
EP1021173A1 (en) 2000-07-26
WO1999018942A1 (en) 1999-04-22

Similar Documents

Publication Publication Date Title
AU9449398A (en) Use of csaidtm compounds for the management of uterine contractions
AU1075699A (en) Hybrid nanofibril matrices for use as tissue engineering devices
AU2791599A (en) Extended release dosage form
AU2863899A (en) New compounds
AUPP608898A0 (en) New use of prostaglandin E2 antagonists
AU5970699A (en) Use
AU4567199A (en) Autoinducer compounds
GB2341180A9 (en) Compounds on the basis of polyalkyl-1-oxa diazaspirodecane compounds
AU2080199A (en) New pharmaceutically active compounds
AU5352198A (en) Location area management
AU4703797A (en) Antimycotic gel having high active compound release
AUPP584198A0 (en) New use
AU136486S (en) An applicator for the vaginal ring
AU6328799A (en) Organophosphorous compounds and use thereof
AU6235799A (en) New use
AU2863799A (en) New compounds
AU6134298A (en) Conformable structures
AUPP059897A0 (en) New use of bicozamycin
AU4813399A (en) New use
AUPP505898A0 (en) New use
AUPP195598A0 (en) New use
AU4812199A (en) New use
AUPP299298A0 (en) New use
AU3056399A (en) New use
AUPP505698A0 (en) New use

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase